[Clinical evaluation of cefminox in children].
In a total of 13 children with infections, ranging in age from 1 month to 6 years, cefminox (CMNX, MT-141), a new antibiotic of cephem group, was administered 14 times and its absorption, excretion, clinical results and safety were determined. Following intravenous drip infusion of CMNX, high blood level was achieved, with half-life of about 1 hour (0.77 to 1.13 hours). The urinary recovery rate was approximately 80% within the first 6 hours after completion of administration. Clinical results were rated as effective in 8 out of 12 assessable cases (66.7%). In any of the cases treated no side effects developed nor any abnormal changes in laboratory finding were observed. From these results, CMNX is considered to be a new antibiotic useful and safe for use in the field of pediatrics.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011014:Pneumonia / Q000188:drug therapy*; D011704:Pyelonephritis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox